Lasting remission following multimodal treatment in a patient with metastatic breast cancer

Anti-Cancer Drugs

Volumn 16, Issue 10, 2005, Pages 1135-1137

  Stemmler, H J ^a   Menzel, H ^b   Salat, C ^c   Lindhofer, H ^d   Kahlert, S ^e   Heinemann, V ^a   Kolb, H J ^a,f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Oncological Practice   (Germany)

^d TRION Pharma GmbH   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

High dose chemotherapy; Metastatic breast cancer; Stem cell transplantation; T cell reinfusion; Trifunctional antibody

Indexed keywords

ANTIBODY; CYCLOPHOSPHAMIDE; EPIRUBICIN; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY CD3; PACLITAXEL; THIOTEPA; TRIFUNCTIONAL ANTIBODY; UNCLASSIFIED DRUG;

ACCESSORY CELL; ADULT; ANTIBODY SPECIFICITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CASE REPORT; CHILL; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; INFLAMMATION; LEUKAPHERESIS; LIVER DYSFUNCTION; LIVER METASTASIS; MUCOSA INFLAMMATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES; ANTIGENS, CD3; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; COMBINED MODALITY THERAPY; EPIRUBICIN; FEMALE; HUMANS; LEUKAPHERESIS; LIVER NEOPLASMS; PACLITAXEL; REMISSION INDUCTION; THIOTEPA; TREATMENT OUTCOME;

EID: 27644472767     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000180122.24031.13     Document Type: Article

References (11)

1. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349:7-16.
2. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000; 342:1069-1076.
3. Bojko P, Welt A, Schleucher R, Borquez D, Scheulen MEVU, Poettgen U, et al. High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplant 2004; 34:637-643.
4. Nieto Y, Shpall EJ, McNiece IK, Nawaz S, Beaudet J, Rosinski S, et al. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clin Cancer Res 2004; 10:5076-5086.
5. Fagnoni FF, Lozza L, Zibera C, Zambelli A, Gibelli N, Oliviero B, et al. Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation. Bone Marrow Transplant 2003; 31:31-38.
6. Lindhofer H, Menzel H, Gunther W, Hultner L, Thierfelder S. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Blood 1996; 88:4651-4658.
7. Weiner GJ. Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice. Int J Cancer Suppl 1992; 7:63-66.
8. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163:1246-1252.
9. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumor cells. Br J Cancer 2000; 83:261-266.
10. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98:2526-2534.
11. Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S, et al. Combined treatment of metastatic breast cancer (MBC) by high dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. Anticancer Res 2005; 25:3047-3054.